Glaucoma News and Research

Latest Glaucoma News and Research

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Shire plc, the global specialty biopharmaceutical company, today announced that a Phase 3b study published in Behavioral and Brain Functions found adults with Attention Deficit Hyperactivity Disorder who took once-daily Vyvanse (lisdexamfetamine dimesylate) Capsules CII demonstrated significant improvement in attention.

6 Aug 2010

Sunridge signs distribution agreement with Ameco Medical Equipment

Sunridge International announced today that it has signed an agreement with Ameco Medical Equipment L.L.C. for distribution rights in several Middle Eastern countries. The five-year contract valued at over 6.5 million dollars will start immediately.

4 Aug 2010

Research links body weight to glaucoma risk

This month's Ophthalmology journal includes surprising research from the Massachusetts Eye and Ear Infirmary on the relation of body weight to the risk for glaucoma. Also, from researchers at the Tokyo Medical and Dental University, comes the first specific map of how the development of myopic maculopathy, an illness that afflicts many severely nearsighted people, predicts which patients will be most susceptible to vision loss.

3 Aug 2010

Hospitals seek new ways to streamline care

News outlets report on hospital issues, including the differences between for-profit and nonprofit hospitals and efforts to streamline care.

2 Aug 2010

Study on link between SNP and concentrations of serum creatinine

Scientists at deCODE genetics and colleagues at Radboud University in the Netherlands today describe how the impact of a single letter variation in the sequence of the human genome conferring risk of kidney disease varies with age and with the onset of other diseases. The study provides independent confirmation of the association made in an earlier study between a version of the the SNP, located on chromosome 16p12, and risk of chronic kidney disease. It also confirmed the link between the SNP and concentrations of serum creatinine, a key indicator of kidney function.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

NEI, FDA to sponsor Glaucoma Endpoints conference

The National Eye Institute and the Food and Drug Administration are sponsoring a Glaucoma Endpoints conference on September 24, 2010, to develop definitions and standards for describing structural changes in the glaucomatous optic nerve and functional changes in vision, as criteria for approval of new glaucoma therapeutics in clinical trials. The one-day meeting will take place at the Natcher Center, National Institutes of Health in Bethesda, Md.

28 Jul 2010

QLT second-quarter total revenue increases 15.4% to $12.4 million

QLT Inc. today reported financial results for the second quarter ended June 30, 2010. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

27 Jul 2010

Alcon second-quarter adjusted EPS increases 14.4% to $2.22 per share

The Alcon Independent Director Committee noted today that Alcon once again delivered strong earnings in the second quarter of 2010. Alcon's 2Q 2010 Adjusted EPS of $2.22 per share represented a year-over-year growth rate of 14.4% and exceeded Wall Street's mean consensus estimate of $2.03 per share by 9.4%. Alcon's strong EPS growth was driven by an 11.3% increase in organic sales resulting, in part, from a 22.3% increase in advanced technology intraocular lens sales, a 17.2% increase in glaucoma sales and a 24.2% increase in emerging market sales.

27 Jul 2010

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Alcon, Inc. reported that global sales rose 12.5 percent to $1.89 billion for the second quarter of 2010, or 11.3 percent excluding the impact of foreign exchange fluctuations and acquisitions. Revenue from acquisitions added 40 basis points to sales growth in the quarter, while foreign currency fluctuations added 80 basis points of growth.

27 Jul 2010

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

22 Jul 2010

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

The American Health Assistance Foundation (AHAF) today announced a new partnership with BioMed Central's open access journal, Molecular Neurodegeneration (MN) in which the publication will be the official open access journal of AHAF.

21 Jul 2010

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

deCODE genetics and ARUP Laboratories today announced a partnership through which ARUP will offer deCODE's DNA-based prostate cancer risk assessment test to its clients nationwide.

20 Jul 2010

New myopia control technology for eye health benefits from Vision CRC

Scientists from the Vision Cooperative Research Centre in Australia have announced that myopia, or short-sightedness, can be controlled with new technology. This ground breaking discovery was based on research conducted by Vision CRC partners – the University of Houston College of Optometry and the Brien Holden Vision Institute, located at the University of New South Wales.

15 Jul 2010

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

ISTA Pharmaceuticals, Inc., today announced it has initiated a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group study will evaluate the safety and efficacy of three concentrations of bepotastine besilate, dosed twice daily, in an Environmental Exposure Chamber model of allergic rhinitis caused by natural exposure to seasonal allergens.

14 Jul 2010

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries across Europe and North America today report the discovery of a common single-letter variation (SNP) in the sequence of the human genome conferring risk of a range of vascular diseases. The SNP confers risk of abdominal aortic aneurysm (AAA), early-onset heart attack, peripheral artery disease (PAD), and pulmonary embolism, independent of other known risk factors.

12 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Glaucoma News and Research

Latest Glaucoma News and Research

ACADIA second-quarter net loss decreases to $4.3 million

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Vyvanse Capsules CII demonstrates significant improvement in adults with ADHD: Phase 3b study

Sunridge signs distribution agreement with Ameco Medical Equipment

Research links body weight to glaucoma risk

Hospitals seek new ways to streamline care

Study on link between SNP and concentrations of serum creatinine

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

NEI, FDA to sponsor Glaucoma Endpoints conference

QLT second-quarter total revenue increases 15.4% to $12.4 million

Alcon second-quarter adjusted EPS increases 14.4% to $2.22 per share

Alcon second-quarter global sales increase 12.5% to $1.89 billion

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

AHAF enters new partnership with BioMed Central's Molecular Neurodegeneration journal

ARUP enters partnership to offer deCODE's DNA-based prostate cancer risk assessment test

New myopia control technology for eye health benefits from Vision CRC

Phase 1/2 clinical study of bepotastine besilate nasal spray initiated for seasonal allergic rhinitis

Common SNP in sequence of human genome conferring risk of vascular diseases discovered

Shire receives FDA approval of Daytrana for ADHD in adolescents

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Glaucoma News and Research

Latest Glaucoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in